04:19 AM EDT, 09/16/2024 (MT Newswires) -- MaxCyte ( MXCT ) said Sunday that it had entered into a strategic platform license agreement with Kamau Therapeutics.

Under the agreement, Kamau obtains non-exclusive research, clinical, and commercial rights to use MaxCyte's ( MXCT ) flow electroporation technology and ExPERTTM platform.

The company said it is entitled to receive annual licensing fees and program-related revenue in return.

Price: 4.0000, Change: -0.03, Percent Change: -0.74